Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call reflects strong financial performance with an adjusted EBITDA significantly above expectations and substantial cash reserves. Raised revenue and margin guidance for 2025, alongside strategic investments in product development and market expansion, indicate a positive outlook. The Q&A section showed confidence in growth and market penetration, particularly for Decipher and MRD platforms. Despite some uncertainties in guidance specifics, the overall sentiment is positive, with strategic initiatives likely to drive stock price upward within the next two weeks.
Key Financial Performance
Core testing business revenue growth 18% year-over-year after adjusting for Envisia, driven by volume growth of 26% in Decipher and 13% in Afirma.
Total revenue $132 million, a 14% year-over-year increase, despite the expected dilutive impact of removing biopharma and other revenue tied to SAS.
Adjusted EBITDA margin 30%, a 650 basis point improvement from the prior year, attributed to disciplined portfolio focus.
Decipher test volume 26,700 tests in Q3, marking the 14th consecutive quarter of over 25% year-over-year volume growth.
Afirma test volume 13% volume growth in Q3, driven by new account wins and increased utilization per account.
Total testing volume 45,900 tests, an 18% increase over the same period in 2024.
Testing revenue $127.8 million, a 17% year-over-year increase, driven by Decipher and Afirma revenue growth of 26% and 7%, respectively.
Testing ASP (Average Selling Price) $2,925, a decrease of 2% compared to the prior year, primarily due to higher prior period collections in Q3 2024 and the Afirma Laboratory Benefit Manager impact.
Product revenue $3.3 million, up 4% year-over-year.
Biopharmaceutical and other revenue $800,000, a decrease compared to $3.1 million in Q3 2024, due to Veracyte SAS restructuring and liquidation proceedings.
Non-GAAP gross margin 73%, up approximately 150 basis points compared to the prior year period.
Testing gross margin 74%, roughly flat to the prior year, driven by improved lab efficiencies.
Product margin 52%, approximately 800 basis points higher than the prior year.
Non-GAAP operating expenses $58.6 million, up 2% year-over-year.
Research and development expenses $14 million, a $2 million decrease, primarily due to the deconsolidation of Veracyte SAS.
Sales and marketing expenses $22.4 million, a $1.5 million increase, driven by higher personnel costs supporting Decipher and Afirma.
G&A expenses $22.3 million, a $1.5 million increase, primarily due to project-related expenses within support functions.
GAAP net income $19.1 million, including a $6.7 million loss upon deconsolidation of Veracyte SAS.
Adjusted EBITDA $39.7 million or 30.1% of revenue, well above expectations due to prior period collections, lab efficiencies, and timing of project investments.
Cash from operations $44.8 million, ending the quarter with $366 million in cash and cash equivalents.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Decipher: Delivered approximately 26,700 tests in Q3, marking the 14th consecutive quarter of over 25% year-over-year volume growth. Expanded clinical evidence for advanced disease, including high-risk localized and metastatic patients. New molecular features like PORTOS and PTEN to be added to Decipher report next year. Increasingly recognized as the standard of care in prostate cancer. Expanded use in high-risk localized and metastatic patients, with significant growth in test volumes.
Afirma: Achieved 13% volume growth in Q3. Transitioned over 1/3 of samples onto new v2 transcriptome workflow, with full transition expected by year-end. Supported 12 Afirma-related abstracts at the 2025 American Thyroid Association meeting.
TrueMRD: Progressed with whole genome-based MRD platform. Multiple studies completed in various cancers, with 10 studies in testing/analysis and 13 in contracting. First phase of NEO-BLAST trial underway for muscle invasive bladder cancer (MIBC). Commercial launch expected in the first half of 2026. Positioned to capture a meaningful share of the pan-cancer market with a differentiated approach. Leveraging Decipher channel to reach approximately 70% of MIBC patients.
Prosigna: On track to launch as an LDT for the U.S. breast cancer market in mid-2026. Supported by clinical outcomes data from the 10-year OPTIMA PRELIM study and other studies demonstrating its utility in guiding preoperative therapy.
Revenue Growth: Achieved 14% year-over-year revenue growth to approximately $132 million in Q3. Testing revenue grew 17% year-over-year, driven by Decipher and Afirma.
Profitability: Adjusted EBITDA margin reached a record 30%, a 650 basis point improvement from the prior year. Raised 2025 adjusted EBITDA margin guidance to exceed 25%.
Operational Efficiency: Improved lab efficiencies contributed to higher testing gross margins. Transitioned Afirma samples to new workflow, enabling more patients to get test results.
Investment in Growth: Accelerating investments in critical projects while maintaining a strong financial profile. Focused on advancing MRD, Prosigna, and IVD products.
Pipeline Development: Launched Decipher Metastatic, completed NIGHTINGALE lung cancer trial enrollment, and deployed v2 transcriptome assay. Robust pipeline with multiple new products and capabilities introduced in the past two years.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The restructuring proceedings of Veracyte SAS and its impact on biopharmaceutical and other gross margins indicate potential regulatory or operational challenges in international markets.
Supply chain disruptions: Transition to a contract manufacturing model for product production may lead to a decline in product gross margin in Q4, indicating potential supply chain or operational risks.
Economic uncertainties: The decrease in testing ASP by 2% compared to the prior year, driven by higher prior period collections and the Afirma Laboratory Benefit Manager impact, suggests economic pressures on pricing and revenue.
Strategic execution risks: Accelerated investments into critical projects while maintaining financial performance may pose risks to achieving strategic objectives if not managed effectively.
Market conditions: The decline in biopharmaceutical and other revenue due to the restructuring of Veracyte SAS highlights challenges in maintaining revenue streams in certain market segments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has raised its 2025 total revenue guidance to $506 million to $510 million, up from the prior guidance of $496 million to $504 million. Testing revenue guidance has also been increased to $484 million to $487 million, reflecting a raised Decipher outlook and continued Afirma volume strength. Testing revenue growth is now estimated at 16%, compared to the prior guidance of 14% to 15%.
Adjusted EBITDA Margin Guidance: The adjusted EBITDA margin guidance for 2025 has been raised to exceed 25%, up from the previous guidance of 23.5%. This reflects year-to-date profitability outperformance and expectations for accelerated investment in the fourth quarter to support strategic growth drivers. Adjusted EBITDA margin is expected to be approximately 25% in the fourth quarter and in future years, barring specific incremental investments.
Decipher Growth Prospects: The company expects durable double-digit growth for Decipher in the long term, supported by expanding clinical evidence and ongoing prospective studies. Decipher is increasingly becoming the standard of care in prostate cancer, with a long runway for growth.
Afirma Transition and Growth: The transition of Afirma to the v2 transcriptome is on track to be completed by year-end 2025. The company expects this transition to enhance operational efficiency and enable more patients to receive test results. Afirma volume growth is expected to remain strong, driven by new account wins and increased utilization per account.
MRD Platform Launch: The company plans to launch its whole genome-based MRD platform, TrueMRD, for muscle invasive bladder cancer (MIBC) in the first half of 2026, with reimbursement. Indication expansion is planned annually to serve more patients across various cancers.
Prosigna Launch: Prosigna is on track to launch as a laboratory-developed test (LDT) for the U.S. breast cancer market in mid-2026. The company sees a tremendous opportunity for Prosigna, supported by clinical outcomes data and ongoing studies demonstrating its utility in guiding preoperative therapy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do clinicians manage discordant results between multimodal AI scores and Decipher?
A:Clinicians focus on the gold standard, which is Decipher. If there is a discordant result, such as a Decipher high and a DPAI-based low result, clinicians prioritize the Decipher result to avoid undertreating the patient. The new technology loses credibility if it lacks sufficient evidence.
Q:What are the internal digital pathology efforts and timelines?
A:The company is leveraging over 200,000 transcriptomes and pathology scanning of whole slide images to develop DPAI models and molecular features. They are collaborating with top investigators and focusing on predictive signatures like LUM-B and P10 activity. The goal is to bring digital pathology into the clinic in a complementary and rigorous way.
Q:How is the company balancing margin trajectory with investment opportunities?
A:The company plans to manage to an approximate 25% adjusted EBITDA target while accelerating investments in areas like the breast channel, MRD, and Prosigna launch. They are hiring new staff, conducting clinical trials, and prioritizing strategic investments to drive future growth.
Q:What is the expected growth for Decipher in 2026?
A:The company expects Decipher to grow more than 20% in volumes in 2026, supported by market penetration, evidence development, and NCCN guidelines. They are confident in achieving durable double-digit growth for the foreseeable future.
Q:What is the company's MRD strategy and differentiation?
A:The company is focusing on muscle invasive bladder cancer (MIBC) as the initial market for its MRD test. They aim to differentiate through the performance of their test, clinical evidence, and commercial channel. They are investing in clinical trials and leveraging their history of evidence development to compete effectively.
Q:What is the company's approach to expanding the breast channel and Prosigna launch?
A:The company plans to build a sales channel focused on breast cancer oncologists in a measured way, similar to their approach with Decipher. They will leverage GRID, collaborate with key opinion leaders, and scale the sales team based on demand. The Prosigna LDT is expected to launch midway through 2026.
Q:What is the overlap between urologists treating prostate cancer and those treating muscle invasive bladder cancer?
A:There is a high overlap, with the company expecting to serve upwards of 70% of the TAM for muscle invasive bladder cancer through their existing channels.
Q:How does the company plan to expand TrueMRD to other indications?
A:The company will prioritize markets where they have an inherent advantage, such as existing channels or unmet needs. They will focus on building a comprehensive care continuum and consider cohort availability and existing data. They are open to entering competitive markets if their whole genome-based approach offers differentiation.
Q:What is the company's approach to M&A and capital allocation?
A:The company prioritizes investing in its business, including clinical trials and product development. They are open to M&A opportunities but remain diligent and selective. They do not feel pressured to spend cash and maintain a disciplined approach to capital allocation.
Q:What is the company's perspective on the competitive landscape for Decipher?
A:The company believes Decipher has taken more market share than expected, supported by NCCN guidelines and evidence development. They view noise around DPAI as lacking substance in terms of market share impact.
Q:What is the company's plan for Molecular Features Reports?
A:The company aims to enhance clinical decision-making by adding predictive signatures to the Decipher report. These features address unmet needs in managing high-risk and metastatic patients and are part of a repeatable formula enabled by GRID and whole transcriptome approaches.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the financial impact of the v2 transcriptome transition, stating only that it is one of the levers for fueling investments. They also did not quantify the expected revenue from the Prosigna launch or the size of the breast channel investment, citing strategic reasons. Additionally, they did not provide detailed data on the performance of the Molecular Features Reports or the exact timeline for expanding TrueMRD to other indications.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASTRO
Afirma sample
BLAST trial
CRC
DPAI
Dr Chief
ESMO
Investors section
MIBC patient
NEO BLAST
Officer Dr
PORTOS
PTEN
Rebecca
STAMPEDE
TrueMRD
analysis
breast cancer
cancer trial
chemotherapy
collaborator
confidence term
efficacy
example
group
hormone therapy
inhibitor
lung
patient test
post
research prostate
score
signature
standard care
subtype
test prostate
test risk
therapy benefit
workflow
VCYT Transcript
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call reveals strong financial performance with a 12% revenue growth, improved gross margins, and a transition from a net loss to net income. Positive cash flow and controlled expenses further enhance the outlook. Despite the acknowledgment of potential risks, the financials and operational efficiency suggest a positive sentiment. The absence of negative analyst sentiment in the Q&A supports this view. Given these factors, the stock price is likely to see a positive movement in the short term.
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary reflects strong financial performance with a 20% revenue increase and improved margins. The company has raised its revenue and EBITDA margin guidance, indicating confidence in future growth. Strategic initiatives like expanding product offerings and market reach, along with double-digit growth in the oncology segment, are positive signals. The absence of negative market conditions or strategic risks further supports a positive sentiment. Although shareholder return plans are not mentioned, the overall outlook is strong, suggesting a positive stock price movement in the near term.
Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript
Positive11-4
The company's earnings call reflects strong financial performance with an adjusted EBITDA significantly above expectations and substantial cash reserves. Raised revenue and margin guidance for 2025, alongside strategic investments in product development and market expansion, indicate a positive outlook. The Q&A section showed confidence in growth and market penetration, particularly for Decipher and MRD platforms. Despite some uncertainties in guidance specifics, the overall sentiment is positive, with strategic initiatives likely to drive stock price upward within the next two weeks.
VCYT Slides
VCYT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
